Table 3.
ACE Inhibitors | Beta Blockers | Calcium Channel Blockers | Statins | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Dollars (in Millions) | % | Dollars (in Millions) | % | Dollars (in Millions) | % | Dollars (in Millions) | % | Dollars (in Millions) | % | |
Actual sales in 2005 | $3,855.77 | $5,232.08 | $5,282.09 | $20,881.85 | $35,251.79 | |||||
Savings possible | ||||||||||
100% of substitutions achieved | $280.13 | 7.3 | $213.84 | 4.1 | $1,015.16 | 19.2 | $1,249.80 | 6.0 | $2,758.93 | 7.8 |
50% of substitutions achieved | $140.07 | 3.6 | $106.92 | 2.0 | $507.58 | 9.6 | $624.90 | 3.0 | $1,379.47 | 3.9 |
25% of substitutions achieved | $70.03 | 1.8 | $53.46 | 1.0 | $253.79 | 4.8 | $312.45 | 1.5 | $689.73 | 2.0 |
Distribution of savings | ||||||||||
% from generic substitution | 14.9 | 96.5 | 22.5 | 56.0 | 0.0 | |||||
% from therapeutic substitution | 85.1 | 3.5 | 77.5 | 44.0 | 0.0 |